This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Peregrine Pharmaceuticals, Inc.
Drug Names(s): 131I-chTNT-1/B MAb
Description: Cotara is a chimeric tumor-necrosis therapy (TNT) antibody attached to Iodine-131, a radioactive agent. Cotara binds to histone H1/DNA complexes exposed in the necrotic core of malignant solid tumors. While Cotara is capable of binding to all nuclear histones (i.e., those found in non-tumor and tumor cells); preclinical studies indicate that it does not penetrate healthy cells with an intact cell membrane.
Deal Structure: In May 2010, Peregrine Pharmaceuticals and Stason Pharmaceuticals announced agreements granting Stason certain exclusive development and commercialization rights to Peregrine's tumor necrosis therapy (TNT) technologies. Peregrine's lead TNT product candidate is Cotara.
Under the terms of the agreements, Stason is acquiring from Peregrine exclusive rights to Peregrine's TNT technologies in certain Asia-Pacific Economic Cooperation (APEC) countries. Peregrine has retained exclusive rights to its TNT technologies in the United States, European Union countries, and other select countries internationally. The agreements also include certain non-exclusive licenses for Peregrine's proprietary radiolabeling technologies and its fully-human NHS76 TNT antibody to enable and accelerate Stason's development of TNT products.
Stason will pursue drug development, clinical trial and commercialization activities in its exclusive APEC territories and both Stason and Peregrine will have the right...See full deal structure in Biomedtracker
Partners: Stason Pharmaceuticals, Inc.
Additional information available to subscribers only: